Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cheng Hao

Showing results (1021-1030 of 1,049) with videos related to

Pageof 105
Sort By:
Gut|September 5, 2015
Sequential therapy for 10 days versus triple therapy for 14 days in the eradication of <i>Helicobacter pylori</i> in the community and hospital populations: a randomised trialJyh-Ming Liou, Chieh-Chang Chen, Chi-Yang Chang, et al.
The Journal of Antimicrobial Chemotherapy|May 31, 2018
14 day sequential therapy versus 10 day bismuth quadruple therapy containing high-dose esomeprazole in the first-line and second-line treatment of Helicobacter pylori: a multicentre, non-inferiority, randomized trialJyh-Ming Liou, Chieh-Chang Chen, Yu-Jen Fang, et al.
Therapeutic Advances in Gastroenterology|August 22, 2020
Comparison of the effect of clarithromycin triple therapy with or without <i>N</i>-acetylcysteine in the eradication of <i>Helicobacter pylori</i>: a randomized controlled trialChieh-Chang Chen, Jiing-Chyuan Luo, Yu-Jen Fang, et al.
The Lancet. Gastroenterology & Hepatology|December 22, 2022
Second-line levofloxacin-based quadruple therapy versus bismuth-based quadruple therapy for Helicobacter pylori eradication and long-term changes to the gut microbiota and antibiotic resistome: a multicentre, open-label, randomised controlled trialJyh-Ming Liou, Xiao-Tao Jiang, Chieh-Chang Chen, et al.
Lancet (London, England)|October 23, 2016
Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trialJyh-Ming Liou, Yu-Jen Fang, Chieh-Chang Chen, et al.
Helicobacter|September 22, 2025
Overall and Stratified Accuracies of H. pylori Serology Testing: A Multicenter Study of 8497 Screening-Naïve AdultsMei-Jyh Chen, Yu-Jen Fang, Chien-Chuan Chen, et al.
Journal of Biomedical Science|September 5, 2020
Copy number variant hotspots in Han Taiwanese population induced pluripotent stem cell lines - lessons from establishing the Taiwan human disease iPSC Consortium BankChing-Ying Huang, Ling-Hui Li, Wan-Tseng Hsu, et al.
Liver Cancer|July 9, 2026
Addition of Intra-Arterial Therapy to Immunotherapy Improves Outcomes in Unresectable Hepatocellular Carcinoma: Taiwan Multicenter Cohort StudyTeng-Yu Lee, Pei-Chang Lee, Ying-Chun Shen, et al.
Hepatology Communications|January 13, 2021
Effects of Cirrhosis and Diagnosis Scenario in Metabolic-Associated Fatty Liver Disease-Related Hepatocellular CarcinomaVincent L Chen, Ming-Lun Yeh, Ju Dong Yang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 4, 2024
Antiviral Therapy Utilization and 10-Year Outcomes in Resected Hepatitis B Virus- and Hepatitis C Virus-Related Hepatocellular CarcinomaDaniel Q Huang, Joseph K Hoang, Rubayet Kamal, et al.
Pageof 105

Showing results (1021-1030 of 1,049) with videos related to

Sort By:
Pageof 105
Gut|September 5, 2015
Sequential therapy for 10 days versus triple therapy for 14 days in the eradication of <i>Helicobacter pylori</i> in the community and hospital populations: a randomised trialJyh-Ming Liou, Chieh-Chang Chen, Chi-Yang Chang, et al.
The Journal of Antimicrobial Chemotherapy|May 31, 2018
14 day sequential therapy versus 10 day bismuth quadruple therapy containing high-dose esomeprazole in the first-line and second-line treatment of Helicobacter pylori: a multicentre, non-inferiority, randomized trialJyh-Ming Liou, Chieh-Chang Chen, Yu-Jen Fang, et al.
Therapeutic Advances in Gastroenterology|August 22, 2020
Comparison of the effect of clarithromycin triple therapy with or without <i>N</i>-acetylcysteine in the eradication of <i>Helicobacter pylori</i>: a randomized controlled trialChieh-Chang Chen, Jiing-Chyuan Luo, Yu-Jen Fang, et al.
The Lancet. Gastroenterology & Hepatology|December 22, 2022
Second-line levofloxacin-based quadruple therapy versus bismuth-based quadruple therapy for Helicobacter pylori eradication and long-term changes to the gut microbiota and antibiotic resistome: a multicentre, open-label, randomised controlled trialJyh-Ming Liou, Xiao-Tao Jiang, Chieh-Chang Chen, et al.
Lancet (London, England)|October 23, 2016
Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trialJyh-Ming Liou, Yu-Jen Fang, Chieh-Chang Chen, et al.
Helicobacter|September 22, 2025
Overall and Stratified Accuracies of H. pylori Serology Testing: A Multicenter Study of 8497 Screening-Naïve AdultsMei-Jyh Chen, Yu-Jen Fang, Chien-Chuan Chen, et al.
Journal of Biomedical Science|September 5, 2020
Copy number variant hotspots in Han Taiwanese population induced pluripotent stem cell lines - lessons from establishing the Taiwan human disease iPSC Consortium BankChing-Ying Huang, Ling-Hui Li, Wan-Tseng Hsu, et al.
Liver Cancer|July 9, 2026
Addition of Intra-Arterial Therapy to Immunotherapy Improves Outcomes in Unresectable Hepatocellular Carcinoma: Taiwan Multicenter Cohort StudyTeng-Yu Lee, Pei-Chang Lee, Ying-Chun Shen, et al.
Hepatology Communications|January 13, 2021
Effects of Cirrhosis and Diagnosis Scenario in Metabolic-Associated Fatty Liver Disease-Related Hepatocellular CarcinomaVincent L Chen, Ming-Lun Yeh, Ju Dong Yang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 4, 2024
Antiviral Therapy Utilization and 10-Year Outcomes in Resected Hepatitis B Virus- and Hepatitis C Virus-Related Hepatocellular CarcinomaDaniel Q Huang, Joseph K Hoang, Rubayet Kamal, et al.
Pageof 105